Annexon (ANNX) highlighted its 2026 strategic priorities and key milestones for its lead programs. Key highlights include: Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barre Syndrome; BLA Submission with U.S./European Data Planned in 2026; Vonaprument Pivotal Phase 3 Topline Data for Dry AMD with Geographic Atrophy on Track for Second Half of 2026 Evaluating Unprecedented Effect on Vision Protection; Proof-of-Concept Data for ANX1502, the First Oral C1 Inhibitor for Autoimmune Disease, Expected in 2026
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX: